Caladrius Biosciences to Participate in the Inv€$tival Showcase in Partnership with Jefferies and the Jefferies 2018 London...
November 09 2018 - 8:30AM
Caladrius Biosciences to Participate in
the Inv€$tival Showcase in Partnership with
Jefferies and the Jefferies 2018 London Healthcare
Conference
BASKING RIDGE, N.J. (November 9, 2018) –
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a development-stage biopharmaceutical company with
multiple technology platforms targeting autoimmune and select
cardiovascular indications, announced today that management will
participate at the following investor conference in November:
Inv€$tival Showcase in Partnership with Jefferies and
the Jefferies 2018 London Healthcare Conference
Date &
Time:
Wednesday, November 14th at 10:30 a.m. GMT, Adelphia
2Presenter:
David J. Mazzo, PhD, President and Chief Executive Officer
Venue:
Waldorf Hilton, Aldwych, London WC2B 4DD
About Caladrius Biosciences
Caladrius is a late-stage therapeutics development
biopharmaceutical company committed to the development of
innovative products that have the potential to restore the health
of people with chronic illnesses. Our leadership team collectively
has decades of biopharmaceutical development experience and
world-recognized scientific achievement in the fields of
cardiovascular and autoimmune disease, among other
areas. The Company’s goal is to build a broad portfolio
of novel and versatile products that address important unmet
medical needs. Our current product candidates include three
developmental treatments for cardiovascular diseases based on our
CD34 cell therapy platform: CLBS12, recipient of SAKIGAKE
designation, in Phase 2 testing in Japan and eligible for early
conditional approval for the treatment of critical limb ischemia;
CLBS14-CMD, in Phase 2 testing for the treatment of coronary
microvascular dysfunction and CLBS14-RfA in late-stage development
for refractory angina for which it has received RMAT designation.
Caladrius’ autoimmune product candidate in Phase 2 testing, CLBS03,
is an ex vivo expanded polyclonal T regulatory cell
therapy for the treatment of recent-onset type 1 diabetes. CLBS03
has been awarded Fast Track and Orphan designations by the
FDA. For more information on the company, please visit
www.caladrius.com.
Contacts:
Investors and Media:Caladrius Biosciences, Inc.John
MendittoExecutive Director, Investor Relations and Corporate
CommunicationsPhone: +1-908-842-0084Email:
jmenditto@caladrius.com
# # #
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024